Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.
about
Transarterial radioembolization for hepatocellular carcinoma: a reviewMicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinomaChallenges of liver cancer: Future emerging tools in imaging and urinary biomarkers.NIMA-related kinase 2 regulates hepatocellular carcinoma cell growth and proliferationComparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.A comparison of the risk factors of intrahepatic recurrence, early recurrencen, and multiple recurrences after resection for single nodular hepatocellular carcinoma.Decreased expression of serum miR-424 correlates with poor prognosis of patients with hepatocellular carcinoma.Association between Pre-Transplant Serum Malondialdehyde Levels and Survival One Year after Liver Transplantation for Hepatocellular CarcinomaHepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinomaSorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.Pediatric hepatocellular carcinoma in a developing country: Is the etiology changing?The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma.Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular CarcinomaTargeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma.What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis.Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.Hippo cascade controls lineage commitment of liver tumors in mice and humans.Higher MELD score increases the overall cost on the waiting list for liver transplantation: a micro-costing analysis based study.Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma.Whole-tumor MRI histogram analyses of hepatocellular carcinoma: Correlations with Ki-67 labeling index.Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality.New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma
P2860
Q26738273-87EA96FF-8D98-492F-AB66-08C1D6B1DBF1Q26751392-D79F1B33-EBF2-45D2-B8D8-D24AFB5F0F51Q30398077-2C32FC53-2461-4C90-9E3A-7631FAA4A331Q33598631-53A2B603-7E8C-494A-8885-518268D5373AQ33728023-817243DC-2EE4-46DF-9CFB-091A8B6AED20Q36056566-557A6EA6-5509-4905-8024-102C6CE2821BQ36464660-36B79593-3421-41F5-802F-7892A91D1968Q36847028-9C97417E-4097-405E-80C5-F7BBD5AF87BCQ36871021-455992C2-6BC4-432C-8AE1-58A85C8D6568Q37582059-F2DD9DAC-B86F-4155-80EF-404599496D3EQ38635603-FEA8727A-86AF-4BD0-BA06-EF90B7453F70Q38733769-10EE496E-CFCF-42E2-B0D3-340507BB1E02Q39148023-D37B9076-9BD8-4A26-8208-D466A4FB5801Q40516093-D69AA6CC-2C79-4AA8-BDB6-1683D06E14D9Q40573712-7B2BEE37-D234-45F0-AEE5-48686A1CBE6EQ41191656-4C870F89-A862-465E-B576-ECF57E2A253BQ42343453-A08985F4-089C-4AE1-B023-56413385773FQ47140233-CD037FB8-6140-47EE-92E3-972A61E8128BQ47378147-B536A724-56ED-43CB-97C7-6A81A7944CE4Q49603070-3777E162-7554-4644-BE3E-8B4A4D0C8CFAQ50525560-23F32844-C810-4A39-935D-498FC114FFC5Q53289839-754F9F08-4681-4129-AFEE-C99A574DDC75Q53841468-0A6988CF-06E8-4F65-9021-CC637C595C8CQ55003470-428E7ED4-F6DC-4CDB-9761-1278C8118326Q57482211-347113CB-F8CC-4B7F-A6F5-EC4F4335A189
P2860
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.
@ast
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.
@en
type
label
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.
@ast
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.
@en
prefLabel
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.
@ast
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.
@en
P2860
P356
P1476
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.
@en
P2093
Adam S Bodzin
Ronald W Busuttil
P2860
P304
P356
10.4254/WJH.V7.I9.1157
P577
2015-05-01T00:00:00Z